Protocol summary

Study aim
Determining the Effect of Spirulina Supplementation on the Extended Glasgow Outcome Scale in Patients with Moderate to Severe Traumatic Brain Injury
Design
This is a randomized, double-blind, parallel-group, phase 3 clinical trial involving 130 patients. Randomizer.org is used for randomization.
Settings and conduct
The study is being conducted in Shiraz at Emtiaz Hospital, the trauma center for Fars Province. In this study, the person enrolling patients, the clinical staff, the person assessing the study outcomes, and the statistician are all blinded to the participants' group assignments.
Participants/Inclusion and exclusion criteria
Study inclusion criteria: 1) Glasgow Coma Scale (GCS) score of less than 13 upon admission 2) Abbreviated Injury Scale (AIS) score greater than 3 for the head region and less than 3 for other body regions 3) Age between 15 and 65 years. study exclusion criteria: 1) History of significant brain injuries, including stroke or prior craniotomy 2) pregnancy or breast feeding 3) Occurrence of cardiorespiratory arrest upon arrival 4) Patients with critical traumatic brain injury (TBI) with a GCS score of 3 or 4, accompanied by fixed, dilated pupils. 5) INR more than 1.4 on admission.
Intervention groups
The intervention group receives a 9-gram dose of Spirulina solution once daily for 14 days or until discharge. Administration begins on the first day following the initiation of enteral feeding in the ICU, delivered either orally or via nasogastric (NG) tube, depending on the patient's condition. control group receives a solution with identical color, viscosity and weight to spirulina solution, once a day for 14 days or until discharge, orally or via NG tube.
Main outcome variables
glascow outcome scale extended , length of ICU hospitalization , length of whole hospitalization , amount of weight gain

General information

Reason for update
Acronym
SSS
IRCT registration information
IRCT registration number: IRCT20220220054079N2
Registration date: 2026-11-14, 1405/08/23
Registration timing: registered_while_recruiting

Last update: 2026-11-14, 1405/08/23
Update count: 0
Registration date
2026-11-14, 1405/08/23
Registrant information
Name
Zahra Eghlidos
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 71 3622 4078
Email address
eghlidos.zahra@gmail.com
Recruitment status
recruiting
Funding source
Expected recruitment start date
2026-10-23, 1405/08/01
Expected recruitment end date
2027-12-22, 1406/10/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Efficacy of Spirulina Supplementation on Glasgow Outcome ScaleExtended in Patients with Moderate to Severe Traumatic Brain Injury a double-blind, randomized controlled clinical trial
Public title
The Effect of Spirulina Supplementation on Traumatic Brain Injury
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
age 15-65 years old GCS on admission less than 13 AIS more than 3 in head and less than 3 in other areas
Exclusion criteria:
GCS 3-4 with fixed dilated pupils history of significant brain damage like CVA or craniotomy history of rheumatologic and autoimmune disorders pregnancy of breast feeding cardiac arrest on admission Plt count less than 100,000 on admission INR more than 1.4 on admission drug history of current antiplatelet therapy like ASA, Clopidogrel, ticagrelor
Age
From 15 years old to 65 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 130
Randomization (investigator's opinion)
Randomized
Randomization description
Following enrollment, participants are assigned to either the intervention or control group at a 1:1 ratio using block randomization. The randomization sequence is generated and maintained by a second study coordinator—who has no role in patient assessment, data collection, or statistical analysis—using the Randomizer.org website. To ensure allocation concealment, group assignment codes (A and B) are placed in opaque, sealed, and sequentially numbered envelopes; this information is disclosed only to a designated staff member who is not involved in treatment, outcome assessment, or data analysis. This individual is responsible for preparing and administering the intervention to the patient. The Spirulina supplement and the placebo are provided in containers that are identical in shape, size, and appearance, distinguished solely by codes A and B; consequently, patients, healthcare staff, outcome assessors, and the data analyst remain unaware of group assignments, thereby fully maintaining the study's double-blind design. Ultimately, 65 patients will be enrolled in each group.
Blinding (investigator's opinion)
Double blinded
Blinding description
To maintain allocation concealment, following the generation of a randomization sequence using block randomization, group allocation codes (A and B) were placed in opaque, sealed, and numbered envelopes by an independent individual who was not involved in treatment, outcome assessment, or data analysis. The Spirulina supplement and placebo were prepared in identical containers and labeled solely with codes A and B; consequently, patients, healthcare staff, outcome assessors, and the data analyst remained unaware of the group allocations, ensuring the study's double-blind design was fully maintained.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Shiraz University of Medical Sciences
Street address
Shiraz Medical School, Imam Hossein Square, Zand Street, Shiraz
City
Shiraz
Province
Fars
Postal code
7134845794
Approval date
2026-09-07, 1405/06/16
Ethics committee reference number
IR.SUMS.MED.REC.1405.243

Health conditions studied

1

Description of health condition studied
Brain injury
ICD-10 code
S06.2
ICD-10 code description
Diffuse traumatic brain injury

Primary outcomes

1

Description
Glasgow Outcome Scale Extended
Timepoint
1, 3, and 6 months after starting Spirulina
Method of measurement
Glascow outcome scale extended calculator

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: 8 grams of spirulina solution is used once a day for 14 days or until discharge. drug intervention is initiated 24 to 48 hours after admission, and the rout of administration is oral if level of consciousness is adequate, or via NG tube if level of consciousness is not adequate. The raw materials used in this study are provided by the knowledge-based company "Zarkhiz Khak Persia" and the formulation, preparation of the intervention solution and placebo solution are also done by "Saaditab Sina" company. It is worth mentioning that both companies operate under the supervision of the growth center of Shiraz University of Medical Sciences. The intervention solution contains 8 hot cooked spirulina (Spirulina platensis) substances, which are prepared from dried and standardized microalgae, and microbial quality and standards are used. It is prepared as a homogenized suspension in a solvent.
Category
Treatment - Drugs

2

Description
Control group: placebo solution is prepared as a suspension without substances, but with the same volume, color, and viscosity as spirulina solution. placebo solution is started 24 to 48 hours after admission, just like intervention group, and is used for 14 days or until discharge. placebo solution is administered to the patients orally if level of consciousness is adequate, or via NG tube if level of consciousness is not adequate.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Shahid Rajaee Surgical Emergency Center
Full name of responsible person
Amin Niakan
Street address
Shahid Rajaee Surgical Emergency Center, Before Niayesh Boulevard, Shahid Chamran Boulevard, Shiraz
City
Shiraz
Province
Fars
Postal code
۷۱۹۴۸۱۵۷۱۱
Phone
+98 917 315 1104
Fax
Email
aminniakan@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Hamid Mohammadi
Street address
7th floor, central building of Shiraz university of medical sciences, besides red crescent building, Shiraz
City
Shiraz
Province
Fars
Postal code
7134814336
Phone
+98 71 3235 7282
Fax
+98 71 3212 2430
Email
mohammadi219@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shiraz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Hasan Avakh
Position
neurosurgical resident
Latest degree
Medical doctor
Other areas of specialty/work
Neurosurgery
Street address
Shahid Rajaee Surgical Emergency Center, Before Niayesh Boulevard, Shahid Chamran Boulevard, Shiraz
City
Shiraz
Province
Fars
Postal code
۷۱۹۴۸۱۵۷۱۱
Phone
+98 993 378 9672
Email
doctor.hassan.avakh.۱۹۹۳@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Hasan Avakh
Position
neurosurgical resident
Latest degree
Medical doctor
Other areas of specialty/work
Neurosurgery
Street address
Shahid Rajaee Surgical Emergency Center, Before Niayesh Boulevard, Shahid Chamran Boulevard, Shiraz
City
Shiraz
Province
Fars
Postal code
۷۱۹۴۸۱۵۷۱۱
Phone
+98 993 378 9672
Email
doctor.hassan.avakh.۱۹۹۳@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Hasan Avakh
Position
neurosurgical resident
Latest degree
Medical doctor
Other areas of specialty/work
Neurosurgery
Street address
Shahid Rajaee Surgical Emergency Center, Before Niayesh Boulevard, Shahid Chamran Boulevard, Shiraz
City
Shiraz
Province
Fars
Postal code
۷۱۹۴۸۱۵۷۱۱
Phone
+98 993 378 9672
Email
doctor.hassan.avakh.۱۹۹۳@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
The entire dataset can be shared once the individuals have been de-identified.
When the data will become available and for how long
Access begins upon the conclusion of the study on December 22, 2027.
To whom data/document is available
It will be available solely to researchers affiliated with academic and scientific institutions, subject to identity verification and the submission of a well-founded request deemed valid by the principal investigator.
Under which criteria data/document could be used
The data are suitable for conducting a systematic review and meta-analysis.
From where data/document is obtainable
Please email Dr. Amin Niakan, the project's principal investigator, to obtain the data. His email address is aminniakan@yahoo.com.
What processes are involved for a request to access data/document
The applicant must provide full particulars, state the reason for requiring the information, and commit to using the data solely for academic and scholarly purposes—within the scope disclosed to the principal investigator—and refraining from any commercial use. It is understood that any violation of these terms is subject to legal action through university ethics committees and the judicial system.
Comments
Loading...